KR20220106974A - 폐동맥 고혈압을 치료하는 방법 - Google Patents

폐동맥 고혈압을 치료하는 방법 Download PDF

Info

Publication number
KR20220106974A
KR20220106974A KR1020227017465A KR20227017465A KR20220106974A KR 20220106974 A KR20220106974 A KR 20220106974A KR 1020227017465 A KR1020227017465 A KR 1020227017465A KR 20227017465 A KR20227017465 A KR 20227017465A KR 20220106974 A KR20220106974 A KR 20220106974A
Authority
KR
South Korea
Prior art keywords
combination therapy
initial
patient
triple combination
pah
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227017465A
Other languages
English (en)
Korean (ko)
Inventor
알렉산드로 마레스타
루아끄 페르슈네
Original Assignee
액테리온 파마슈티칼 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73726769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20220106974(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 액테리온 파마슈티칼 리미티드 filed Critical 액테리온 파마슈티칼 리미티드
Publication of KR20220106974A publication Critical patent/KR20220106974A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227017465A 2019-11-29 2020-11-27 폐동맥 고혈압을 치료하는 방법 Pending KR20220106974A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962941910P 2019-11-29 2019-11-29
US62/941,910 2019-11-29
US202063023452P 2020-05-12 2020-05-12
US63/023,452 2020-05-12
US202063076149P 2020-09-09 2020-09-09
US63/076,149 2020-09-09
PCT/EP2020/083593 WO2021105331A1 (en) 2019-11-29 2020-11-27 Methods of treating pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
KR20220106974A true KR20220106974A (ko) 2022-08-01

Family

ID=73726769

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227017465A Pending KR20220106974A (ko) 2019-11-29 2020-11-27 폐동맥 고혈압을 치료하는 방법

Country Status (18)

Country Link
US (1) US12485119B2 (https=)
EP (1) EP4065119B1 (https=)
JP (3) JP7721520B2 (https=)
KR (1) KR20220106974A (https=)
CN (1) CN114728002A (https=)
AU (1) AU2020392424A1 (https=)
BR (1) BR112022010311A2 (https=)
CA (1) CA3158292A1 (https=)
CR (1) CR20220305A (https=)
EC (1) ECSP22051163A (https=)
ES (1) ES2994089T3 (https=)
IL (1) IL293271A (https=)
JO (1) JOP20220127A1 (https=)
MX (1) MX2022006403A (https=)
PE (1) PE20221320A1 (https=)
PH (1) PH12022551294A1 (https=)
TW (1) TW202133851A (https=)
WO (1) WO2021105331A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024099953A1 (en) * 2022-11-07 2024-05-16 Actelion Pharmaceuticals Ltd Combination of macitentan and tadalafil for the treatment of pulmonary arterial hypertension
KR102663470B1 (ko) * 2023-03-16 2024-05-10 주식회사 케어사이드 폐성 고혈압에 의한 심장 질환 예방 및 심장 치료용 조성물 및 이를 포함하는 기능성 제제

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002227984B8 (en) 2000-12-18 2007-01-04 Actelion Pharmaceuticals Ltd. Novel sulfamides and their use as endothelin receptor antagonists
TWI316055B (https=) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
JP5764061B2 (ja) 2008-08-13 2015-08-12 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ マシテンタン含有治療用組成物
LT2447254T (lt) 2009-06-26 2018-01-10 Nippon Shinyaku Co., Ltd. Kristalai
WO2011024874A1 (ja) 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
MX346730B (es) 2010-10-15 2017-03-30 Gilead Sciences Inc Composiciones y metodos para el tratamiento de la hipertension pulmonar.
EP3136101B1 (en) 2014-04-22 2019-12-25 Tohoku University Method of testing for pulmonary hypertension
CN107427698A (zh) 2015-01-13 2017-12-01 维瓦斯公司 肺高血压的组合疗法
CA3041679A1 (en) 2016-10-27 2018-05-03 Lawrence S. ZISMAN Combination therapy for treating pulmonary hypertension
PT3897646T (pt) * 2018-12-21 2024-07-08 Actelion Pharmaceuticals Ltd Macitentano para tratamento de hipertensão arterial pulmonar

Also Published As

Publication number Publication date
CR20220305A (es) 2022-07-28
BR112022010311A2 (pt) 2022-08-16
PH12022551294A1 (en) 2023-11-20
PE20221320A1 (es) 2022-09-08
US20230032813A1 (en) 2023-02-02
JP7721520B2 (ja) 2025-08-12
JP7620758B2 (ja) 2025-01-23
JP2023504115A (ja) 2023-02-01
EP4065119B1 (en) 2024-09-04
AU2020392424A1 (en) 2022-06-02
JOP20220127A1 (ar) 2023-01-30
ES2994089T3 (en) 2025-01-17
MX2022006403A (es) 2022-08-25
EP4065119A1 (en) 2022-10-05
WO2021105331A1 (en) 2021-06-03
JP2024153734A (ja) 2024-10-29
CN114728002A (zh) 2022-07-08
TW202133851A (zh) 2021-09-16
IL293271A (en) 2022-07-01
ECSP22051163A (es) 2022-07-29
JP2025172745A (ja) 2025-11-26
CA3158292A1 (en) 2021-06-03
US12485119B2 (en) 2025-12-02

Similar Documents

Publication Publication Date Title
EP3661514B1 (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
JP7620758B2 (ja) 肺動脈性肺高血圧症の治療方法
US20110009460A1 (en) Compositions and methods for treating amyotrophic lateral sclerosis
AU2017275650B2 (en) Pharmaceutical combinations
US20220323437A1 (en) Methods for treating pulmonary arterial hypertension
US20140113930A1 (en) Therapeutic combination for cancer treatment
WO2010062640A1 (en) Methods for treating idiopathic pulmonary fibrosis and associated complications
JP2024523559A (ja) アルドステロン合成酵素阻害剤を使用する方法
US20220257595A1 (en) Macitentan for use in treating portopulmonary hypertension
WO2025106686A1 (en) Methods of treating pediatric low-grade glioma
KR20250150635A (ko) 인자 b 억제제의 사용 방법
WO2022238375A1 (en) Methods of treating pulmonary hypertension
WO2024099953A1 (en) Combination of macitentan and tadalafil for the treatment of pulmonary arterial hypertension
WO2026019771A1 (en) Zalunfiban for use in the treatment of thrombotic disorder in patients with renal impairment
HK40082153A (en) Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton’s tyrosine kinase
HK40026724B (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
EA043824B1 (ru) Жидкие лекарственные формы для лечения рака

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902